{"id":4422,"date":"2021-03-10T08:35:59","date_gmt":"2021-03-10T07:35:59","guid":{"rendered":"https:\/\/kompetenz-statt-demenz.dsgip.de\/?p=4422"},"modified":"2021-03-09T18:55:24","modified_gmt":"2021-03-09T17:55:24","slug":"cure-for-alzheimers-disease-is-possible","status":"publish","type":"post","link":"https:\/\/kompetenz-statt-demenz.dsgip.de\/en\/cure-for-alzheimers-disease-is-possible\/","title":{"rendered":"The ReCode program according to Dr. Bredesen – Cure for Alzheimer’s disease is possible"},"content":{"rendered":"

To date, there is no effective drug to treat Alzheimer’s disease. The currently available drug treatment options are limited to acetylcholinesterase inhibitors and memantines, each of which is used depending on the stage of the disease and directly influences the action of neurotransmitters in the brain. It is hard to believe, but these pharmacological approaches are still based on the findings of the 1970s and 1980s.\u00a0<\/span><\/p>\n

Worse, the clinical benefit of these widely prescribed anti-dementia drugs is controversial, as the body can develop adaptive mechanisms and Alzheimer’s symptoms may progress even faster when the drugs are discontinued. Although numerous drug strategies have been attempted in the meantime, clinical trials were discontinued after (at the latest) phase II,\u00a0 because they did not show sufficient efficacy and therefore did not result in significant improvements in the symptoms of Alzheimer’s disease. Thus, the approval of Biogen’s most promising candidate ‘Aducanumab’ – an antibody against the amyloid-beta deposition in the brain –\u00a0 seems to be in great danger: An independent expert panel advising the FDA concluded that the documented benefit is too low and rejected the approval of ‘Aducanumab’.\u00a0<\/span><\/p>\n

But why have all pharmacological monocausal approaches failed so far?\u00a0<\/span><\/p>\n

As early as 2014, the US neurologist Dr. Dale Bredesen correctly recognised that Alzheimer’s disease is a generalised metabolic disorder, i.e. a disease with a variety of causes, which must also be addressed in its multitude when it comes to therapy. Above all, Bredesen showed that such a therapy is effective and that it is therefore possible!\u00a0<\/span><\/p>\n

As an analogy, Bredesen uses the image of a leaky roof through which it rains to imagine Alzheimer’s disease: there are up to 36 holes in the Alzheimer’s roof that need to be patched to make everything sealed again. Not every patient has the same holes, and therefore the protocol is customised based on the patient’s genetics, current health status and lifestyle.\u00a0<\/span><\/p>\n

Also in 2014, Bredesen’s therapy concept, called the ReCODE (‘Reversal of Cognitive Decline’) protocol, was first published in the scientific press. This novel therapy concept is a promising approach in the treatment of Alzheimer’s disease, as it follows a multifactorial strategy.\u00a0<\/span><\/p>\n

In the ReCode protocol, 6 different types of Alzheimer’s disease are defined according to the patient’s genetic variant of the ApoE gene (see KsD page – <\/span>genetics<\/span><\/a>), predominant symptoms and co-existing diagnoses:\u00a0<\/span><\/p>\n

    \n
  1. Inflammatory (“hot”);<\/span><\/li>\n
  2. Atrophic (“cold”);<\/span><\/li>\n
  3. Glycotoxic (“sweet”);\u00a0<\/span><\/li>\n
  4. Toxic (“vile”);<\/span><\/li>\n
  5. Vascular (“pale”) and\u00a0<\/span><\/li>\n
  6. Traumatic (“dazed”).<\/span><\/li>\n<\/ol>\n

    Here, the specific type ultimately determines the therapeutic approach. The effect of each type-specific therapeutic strategy is assessed through a comprehensive cognitive examination, called <\/span>cognoscopy<\/b>, using blood tests, cognitive assessments, and other clinical biomarkers.\u00a0<\/span><\/p>\n

    The fact that the Bredesen method is actually effective, and not an empty promise, has now been demonstrated in a large number of studies. In 2018, for example, Dr. Bredesen reported on 100 successfully treated patients in whom the symptoms of Alzheimer’s disease had progressed to varying degrees, from mild to moderate cognitive impairment.\u00a0<\/span><\/p>\n

    Through measures such as:<\/span><\/p>\n